Strategic-Technological Analysis: MyoSwiss AG
16 pages · PDF · 25 August 2025 · Licensed single-user copy, watermarked to the buyer
€299 excl. VAT — EU VAT calculated at checkout (VAT ID accepted for reverse charge); invoice issued after payment
One click to Stripe — guest checkout, no account. Your download appears on the confirmation page and arrives by e-mail right after payment (link valid 72 hours, up to 5 downloads).
About this report
The MyoSwiss AG story begins in 2017, when two Swiss researchers at ETH Zurich’s Sensory-Motor Systems Lab applied robotics and textile innovation to human mobility. Their flagship Myosuit is a lightweight, garment-style exoskeleton that adds a wearable layer of robotic muscle to a user’s legs.
As a medical device now CE-certified and marketed in Europe , it has drawn notice beyond the rehabilitation community. But MyoSwiss’s technology – soft, sensory-controlled actuation that eases leg load – also intersects with emerging defense concerns. European planners eye advanced human-extension systems as one element of future dismounted capability.
Key questions this report answers
- What does MyoSwiss's Myosuit garment-style exoskeleton do to add a wearable layer of robotic muscle through soft, sensory-controlled actuation?
- How mature is the Myosuit as a CE-certified medical device, and how does it intersect with emerging European dismounted-capability concerns?
- How does MyoSwiss's origin at ETH Zurich's Sensory-Motor Systems Lab shape its partnerships and market beyond rehabilitation?
- What capability gaps and dependencies affect MyoSwiss's dual-use path toward human-extension defence applications?
Inside this report
- Executive Summary
- 1. Corporate Identity & Legal Structure
- 2. Strategic Business Profile
- 3. Technology Portfolio Mapping
- 4. Technology Readiness Assessment
- 5. European Strategic Program Participation
- 6. Academic & Research Origins
- 7. Dual-Use Applications & European Market Strategy
- 8. Strategic Partnerships & European Industrial Alliances
- 9. European Market Focus & Operational Domains
- 10. Intellectual Property & European Innovation Assets
- 11. Leadership & European Technical Expertise
- 12. Capability and Gap Analysis
- 13. Strategic Indicators & European Innovation Metrics
Who it's for
Investors screening MyoSwiss AG, competitors and partners assessing their position, and analysts who need a sourced, structured account of the entity and its technology.
Related reports
Methodology, format & delivery
DFM reports are built from primary and official sources — TED procurement notices, CORDIS and the EU Funding & Tenders Portal, EIB operations, the NATO Innovation Fund portfolio, SIPRI data, official budget documents and company disclosures — read together with the underlying legal texts. Sources are cited in the document; it reflects them as of its publication date (25 August 2025). You receive a 16-page PDF, watermarked to you on every page, delivered on the confirmation page and by e-mail immediately after checkout (personal link valid 72 hours, up to 5 downloads). Guest checkout, single-user licence — Terms of Sale.
Related on DFM
More Tactical reports · Human Enhancement · All reports
Prefer unlimited access?
Prefer unlimited access? Every report like this is included in the DFM Analysis subscription. See plans →